Delivery Order SPE2DE24D0013-SPE2D625F9HP6
- Not listed
- The U.S. Defense Logistics Agency awarded a firm fixed-price delivery order valued at $4,080 to Cepheid Inc. for COVID-19, influenza, and respiratory syncytial virus (RSV) diagnostic solutions. The delivery order, issued on August 22, 2025, with completion targeted for August 29, 2025, represents a continuation of the Medical Supply Chain's procurement of molecular diagnostic testing capabilities. Cepheid, a Sunnyvale, California-based manufacturer specializing in advanced diagnostic systems and...
- The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $5,440 to Cepheid Inc. on August 25, 2025, for the supply of COVID-19, influenza, and respiratory syncytial virus (RSV) diagnostic solutions. This firm fixed-price delivery order, which is not set-aside designated, is scheduled for completion by September 2, 2025, and will be performed at Cepheid's facility in Sunnyvale, California. The award represents a continuation of Cepheid's established role...
- The U.S. Department of Defense Medical Supply Chain awarded a $38,148 firm fixed-price delivery order to Cepheid Inc. for SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) diagnostic solutions. The delivery order, issued on September 15, 2025, with an ultimate completion date of September 26, 2025, represents a continuation of Cepheid's ongoing provision of molecular diagnostic testing capabilities to federal healthcare systems. Cepheid, a Sunnyvale, California-based manufacturer of...
- The U.S. Defense Department's Medical Supply Chain awarded a $7,480 firm fixed-price delivery order to Cepheid Inc., a Sunnyvale, California-based molecular diagnostics manufacturer, on September 5, 2025, with completion targeted for September 19, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, procures diagnostic solutions for detecting COVID-19, influenza, and respiratory syncytial virus (RSV). This award carries no set-aside designation and represents a continuation of Cepheid's...
- The Defense Department's Medical Supply Chain division awarded a $3,400 firm fixed-price delivery order to Cepheid Inc. on July 30, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The contract, designated as delivery order XPCOV2/FLU/RSV-10, is scheduled for completion by August 6, 2025, and will be performed at Cepheid's facility in Sunnyvale, California. This award carries no set-aside designation and represents a...
- The U.S. Defense Medical Supply Chain awarded a $4,080 firm fixed-price delivery order to Cepheid Inc. on August 11, 2025, for diagnostic testing solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV). This delivery order, with an ultimate completion date of August 18, 2025, carries no set-aside designation and represents a focused procurement of molecular diagnostic products or services from the Sunnyvale, California-based manufacturer. The award likely falls under...
- The Defense Department's Medical Supply Chain awarded a $4,080 firm fixed-price delivery order to Cepheid Inc. on July 18, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The contract, designated as XPCOV2/FLU/RSV-10, represents a delivery order with an ultimate completion date of July 25, 2025, and carries no set-aside designation. Work will be performed at Cepheid's facility in Sunnyvale, California. This award reflects...
- The U.S. Defense Department's Medical Supply Chain agency awarded a $3,400 firm fixed-price delivery order to Cepheid Inc. on July 14, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The contract, which is due for completion by July 21, 2025, utilizes no set-aside designation and will be performed at Cepheid's facility in Sunnyvale, California. This delivery order represents a continuation of Cepheid's established role as...
- Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic solutions, was awarded a $3,400 firm fixed-price delivery order on July 28, 2025, for COVID-19, Influenza, and Respiratory Syncytial Virus (RSV) diagnostic testing supplies. The delivery order, contract number 4568910321, is set to be completed by August 4, 2025, and will be performed at Cepheid's Sunnyvale facility. The contract is funded by the Defense Department's Medical Supply Chain entity and utilizes no...
- The U.S. Defense Department's Medical Supply Chain awarded a $17,680 firm fixed-price delivery order to Cepheid Inc. on September 8, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The delivery order, designated XPCOV2/FLU/RSV-10, is set to be completed by September 15, 2025, with performance conducted at Cepheid's headquarters in Sunnyvale, California. This award carries no set-aside designation and represents a...
- SPE2DE24D0013Indefinite Delivery Contract
- SPE2DE24D0013-SPE2D625F9HP6Delivery Order
The U.S. Defense Department's Medical Supply Chain awarded a $4,488 firm fixed-price delivery order to Cepheid Inc. on July 30, 2025, for SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) diagnostic solutions. The delivery order, which carries an ultimate completion date of August 13, 2025, will be performed at Cepheid's headquarters in Sunnyvale, California. This award includes no set-aside designation and represents a near-term procurement from the Sunnyvale-based molecular diagnostics manufacturer, which specializes in GeneXpert diagnostic systems and associated test kits for infectious disease detection. This delivery order likely draws from one of Cepheid's existing indefinite delivery vehicles with the Department of Veterans Affairs, including the $32.8 billion IDV with VA's Veterans Integrated Service Network 6 or the $2.5 million IDV with VA's Veterans Integrated Service Network 21, both of which provide molecular diagnostic testing reagents and assays for conditions including COVID-19, influenza, and RSV. Cepheid's comprehensive federal portfolio demonstrates the company's established capability in supplying critical diagnostic solutions across the federal healthcare system, supporting both Defense and Veterans Affairs agencies' pandemic preparedness and infectious disease management objectives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 7/30/25 |